Anticipated since 2021, the House released a 47-page report on the approval process for the Alzheimer drug Aduhelm (aducanumab), with rapid coverage at WSJ and NYT. WSJ describes the report as, "an 18-month investigation by the Democrat-led House Oversight and Reform Committee and the Energy and Commerce Committee," with quotes from Rep. Maloney (D, NY) and Pallone (D, NJ). WSJ adds, " Republicans didn’t contribute to the report, according to spokespeople from both parties."
Find the report here.
Find the initial NYT article here.
Find the initial WSJ article here.
Find the initial STAT article here.
STAT with focus on pricing here.
Biopharma Dive here.
In other Alzheimer news,
- ICER released a report on health economics-based pricing for lecanemab, news story here.
- An international group reported a better blood test for Alzheimer's based on a new monoclonal for "brain derived tau" - Gonzalez-Ortiz et al., here.
- Bloomberg reported that Fujirebio and others are hot on the trail of an FDA-approvable blood test for Alzheimer's, here.
- Fujirebio already has an FDA-approved, CSF-based Alzheimer test from May 2022.
